Fusion Interactive Corp. (FUIG)

[Xace]

OTCMarketBulls: OTCMarketBulls.com: OTCMB Wants You To Win Up To $20k Sign Up Today and Enter Our Cash GIVEAWAY!! Gentium S.p.A. (NASDAQ: GENT) +5.73%, RuthaEUR(TM)s Hospitality Group, Inc. (NASDAQ: RUTH) +14.08%, SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) +11.86%, Signature Exploration and Production Corp. (OTCBB: SXLP) +87.50%, ubroadcast, inc. (OTCBB: UBCI) +16.00%, Proton Laboratories, Inc (OTC: PLBI) +200.00%

OTCMarketBulls is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring value to shareholders. Some of our past picks had soared as much as 4600%. To view some of our profiled stocks, please visit our website at http://www.otcmarketbulls.com/OTCMBlandingpage.php. ____________________________

GENT LATEST NEWS

Gentium Announces Extension of License and Supply and Cost Sharing Agreements with Sigma-Tau New Agreement Further Strengthens Existing Relationship; Up to $15M in Payments to Gentium

VILLA GUARDIA (Como), Italy--(1-11-10)--Gentium S.p.A. (Nasdaq: GENT ) today announced that it has amended its existing License and Supply and Cost Sharing Agreements with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of Defibrotide in North America, Central America and South America. Gentium will retain exclusive rights to Defibrotide in Europe and the rest of the world.

The License and Supply Agreement has been amended to include a license to Sigma-Tau for the intravenous formulation of Defibrotide for the prevention of veno-occlusive disease (VOD) in the Americas and to transfer the New Drug Application (NDA) post approval in the United States (US). In addition, Gentium and Sigma-Tau have agreed to establish a joint steering committee to discuss in good faith, inter alia, the development, filing and relevant funding of Defibrotide for any therapeutic indication in the territory licensed to Sigma-Tau.

Under the amended terms of the Cost Sharing Agreement, the two companies will continue to share development costs for studies currently required for the filing of an NDA for Defibrotide. In addition, the parties have agreed to negotiate in good faith the funding of certain additional costs that may be required to obtain regulatory approval in the US, and that $1,000,000 of costs reimbursed by Sigma-Tau will be deductible from its future royalty payments due to Gentium under the License and Supply Agreement.

In return for the amended terms, Gentium will receive an initial payment of $7,000,000 from Sigma-Tau in connection with the execution of the amended agreements. An additional payment of $6,000,000 will be due to Gentium following approval from the FDA to market Defibrotide in the US and a further $2,000,000 will be payable following the transfer of the approved NDA to Sigma-Tau. Gentium will continue to receive a 7% royalty on net sales of Defibrotide and a supply margin equal to the greater of 31% of net sales of Defibrotide or EUR50.00 per unit in the Americas.

"We have been collaborating with Sigma-Tau on the development of Defibrotide since 2001 and are delighted to expand this relationship as we move toward completing the studies required for filing an NDA," said Dr. Khalid Islam, Gentium's Chairman and Interim CEO. "We believe that Sigma-Tau is a valuable strategic partner whose aligned interest and marketing know-how in the Americas adds significant value. Moreover, this agreement with Sigma-Tau will strengthen our balance sheet without the issuance of additional shares."

"We believe Defibrotide has the potential to not only treat, but also prevent VOD," said Gregg Lapointe, Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc. "We are focused on developing therapies for rare, orphan diseases and remain committed to working closely with Gentium to make Defibrotide, a potentially lifesaving treatment, available to patients as quickly as possible."

About VOD

Veno-occlusive disease is a potentially life-threatening condition, which typically occurs as an important complication of stem cell transplantation. Certain high-dose chemo-radiation therapy regimens used as part of SCT can damage the lining cells of hepatic blood vessels and so result in VOD, a blockage of the small veins of the liver that leads to liver failure and can result in significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). SCT is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. There is currently no approved agent for the treatment or prevention of VOD in the US or the EU.

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the US Food and Drug Administration and EMEA to prevent and to treat VOD and Fast Track designation by the US FDA for the treatment of severe VOD in recipients of stem cell transplants.

About Sigma-Tau

Sigma-Tau is a leading, international, pharmaceutical group that invests in the research, development and marketing of innovative and effective treatments to improve patient well-being and quality of life. Sigma-Tau has its headquarters in Pomezia (Rome, Italy). A total of 13 NCEs and 12 known molecular entities in 33 different indications are at various stages of development. Among them, several are aimed at rare diseases. Therapeutic areas in which the company's research and development are focused include metabolism, neurology, cardiovascular, oncology and immunology. ____________________________

RUTH LATEST NEWS

Ruth's Hospitality Group, Inc. Sets a Record Date for its Rights Offering and Special Meeting of Stockholders

HEATHROW, Fla.--(1-11-10)--Ruth's Hospitality Group, Inc. (NASDAQ: RUTH) announced today that it has established a record date of January 20, 2010 for its previously announced common stock rights offering.

Under the terms of the rights offering, the Company will distribute at no charge to the holders of its common stock as of the close of business on the record date one transferable subscription right for each share of Company common stock then owned. Each subscription right will entitle the holder to purchase a number of shares of common stock to be determined by the Company's board of directors at an exercise price per share to be determined by the Company's board of directors. The Company currently expects to announce the price per share and the number of shares that may be purchased per right prior to January 15, 2010.

The Company currently expects that the subscription period for the rights offering will begin on the day following the record date and will remain open for approximately 20 days thereafter, although the Company reserves the right to extend the subscription period and to cancel the rights offering at any time. The Company will file a prospectus supplement with the Securities and Exchange Commission detailing the specific terms and conditions of the rights offering.

The Company also announced today that it has established a record date of January 20, 2010 for its previously announced special meeting of stockholders to consider the approval of the proposed sale of $25.0 million of the Company's newly-created Series A 10% Convertible Preferred Stock to affiliates of Bruckmann, Rosser, Sherrill & Co. Management, L.P. in a private placement transaction. The Company's stockholders as of the close of business on the record date will be entitled to vote at the special meeting. The Company has filed a preliminary proxy statement and will file a definitive proxy statement with the Securities and Exchange Commission detailing the specific matters to be considered at the special meeting.

About Ruth's Hospitality Group, Inc.

Ruth's Hospitality Group, Inc. (NASDAQ: RUTH) is a leading restaurant company focused exclusively on the upscale dining segment. The Company owns the Ruth's Chris Steak House, Mitchell's Fish Market, Mitchell's Steakhouse and Cameron's Steakhouse concepts. Ruth's Hospitality Group, Inc. was founded in 1965 and currently has more than 150 Company- and franchisee-owned locations worldwide.

For further information about our restaurants, to make reservations, or to purchase gift cards, please visit: www.RuthsChris.com, www.MitchellsFishMarket.com, www.MitchellsSteakhouse.com and www.Camerons-Steakhouse.com. For more information about Ruth's Hospitality Group, Inc., please visit www.rhgi.com. ____________________________

SCLN LATEST NEWS

SciClone Provides 2009 Financial Update and Initial 2010 Sales Revenue Guidance

FOSTER CITY, CA--(01/11/10) - SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) today announced its full year 2009 sales revenue, 2010 sales revenue guidance and its year-end cash position as follows: ' -- For 2009, the company anticipates revenues of approximately $72.4 million (unaudited), a 34% increase over 2008.

-- Cash, cash equivalents, short and long-term investments are anticipated to be approximately $31.8 million (unaudited) at December 31, 2009, compared with $29.7 million at December 31, 2008.

-- The company expects 2010 sales revenue of $82 to $85 million, a 15% increase over 2009

"During 2009, we executed on our corporate strategy of managing the company as a profit-driven specialty pharmaceutical business with a strong pipeline to fuel future growth. We expect to achieve significant full year operating profitability during 2009 and are very pleased with both our commercial sales growth and cash position," commented Friedhelm Blobel, Ph.D. SciClone's President and Chief Executive Officer. "Given the strong performance of our international commercial operations and careful expense management, we expect profits to continue to grow in 2010. We look forward to providing full 2010 financial guidance as well as an update on our pipeline later this quarter."

SciClone expects to report its full 2009 financial results, and further 2010 financial guidance in early March, in connection with the announcement of its 2009 year-end financial results.

About SciClone

SciClone Pharmaceuticals (NASDAQ:SCLN) is a profit-driven, global specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and overall expense management. ZADAXIN' (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin, in clinical studies as an enhancer of H1N1 flu vaccines; thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead(TM) in China, where the product is under regulatory review. The Company also has exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm(TM) in China and Vietnam, for which it will seek regulatory approval. For additional information, please visit www.sciclone.com. ___________________________

SXLP LATEST NEWS

Signature Exploration Provides Detail on 1st Drill Strategy

HOUSTON, Jan. 11 -- Signature Exploration and Production Corp. (OTC Bulletin Board: SXLP) today provided additional information on the Company's Victoria County, Texas "Koliba" prospect (the "Prospect").

The new well will be drilled to approximately 6,800 feet to test 3 Frio Sand zones. It is believed that Frio geological formation wells usually enjoy lower exploration costs resulting in higher success ratios. Typically, these types of projects have shallower depths and reduced completion costs. Records from the Railroad Commission of Texas, which was established in 1891 and is the oldest regulatory agency of its kind in the nation, state 7 wells from these 3 target zones have produced 390,426 barrels of oil and 2,472,481 MCF (thousand cubic feet) of gas. The new well will be drilled only 250 feet from another that was productive in all three zones.

Steven Weldon, CEO of Signature Exploration and Production Corp., stated, "The neighboring production, the past successes of these targeted zones and the supporting data has convinced us that we should have an extremely productive multiple zone oil and gas well at Koliba."

About Signature Exploration and Production Corp.

Signature Exploration and Production Corp. is an independent energy company engaged in the exploration, development, exploitation and acquisition of on-shore oil and natural gas properties in conventional producing areas along the gulf coast of Texas. Management's strategy is to continue making acquisitions of select properties that have been identified as economically attractive, technically and geologically sound and have significant upside potential. Visit www.signatureexploration.com for more information. ____________________________

UBCI LATEST NEWS

ubroadcast.com Marks 4th Anniversary With Extension of Free Trial Account Offer Growth in Channels and Member-Related Revenues Prompt Extension

SAN DIEGO, CA--(01/11/10) - ubroadcast, inc. (OTC.BB:UBCI), a leader in Internet Broadcasting, today announced that it is celebrating the 4th anniversary of ubroadcast.com by extending the web site's free trial account offer through the first quarter of 2010. The company also advised that its recent growth to 10,000 channels and increase in sign-ups for Broadcaster Packages had been fueled by the free account offer announced late in 2009.

The company plans to release additional Broadcaster Packages and refine its current offering throughout 2010 as it hopes to continue to capitalize on what it feels is the future in web broadcasting and live entertainment.

Broadcasters and viewers can sign up for a free trial account, then start broadcasting LIVE, at www.ubroadcast.com.

About ubroadcast, inc.

UBCI's ubroadcast.com allows users to produce and broadcast LIVE and On Demand television and radio in high quality. By blending this user-generated content and UBCI's own original programming in a single application, UBCI bridges the gap between Internet video and traditional network radio and television.

Rolling Stone magazine, About.com, TechCrunch.com, and ABC News have all given ubroadcast media attention, and The San Diego Business Journal headline stated that the market for ubroadcast programs could be "Larger than MySpace and YouTube." ____________________________

PLBI LATEST NEWS Proton Laboratories, Inc. Announces the Acquisition of Regenobody S.A.

SOSUA BAY, Dominican Republic, Jan 8, 2010 -- Proton Laboratories, Inc. (Pink Sheets:PLBI), a Washington corporation, today announced the acquisition of Regenobody S.A., a Dominican Republic company involved in some of the latest technologies associated with stem cell regeneration using the patient's own stem cells. Pursuant to the Agreement, the Company (PLBI) will issue 300,000,000 of its common shares to the Regenobody shareholders, which will result in the shareholders of Regenobody acquiring shareholder control of Proton Laboratories, Inc.

Armando Casciati, newly elected President of Proton Laboratories, Inc. stated that the new company will aggressively work toward completing the development of its laboratory and acquisition of the balance of the needed equipment from its Korean licensor and patent holder, RNLBIO. It is anticipated that a name change and symbol change will occur in the next 90 days. The prior Proton directors have resigned concurrent with the acquisition. More information may be seen at the Company's website www.regenobody.com. ____________________________

OTCMarketbulls.com is an online financial destination where money managers, analysts, and individual investors can converge to discover new and exciting investment news, opportunities, and ideas. OTCMarketBulls.com is focused on finding emerging growth companies that do not necessarily have widespread analyst coverage on Wall Street. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by OTCMarketBulls.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

For full disclaimer/disclosure: http://www.otcmarketbulls.com/disclaimer.php

Visit Us On Twitter and Facebook: http://twitter.com/otcmarketbulls http://www.facebook.com/otcmarketbulls

SIGN UP FOR OUR FREE NEWSLETTER AND FREE EMAIL ALERTS!! http://www.otcmarketbulls.com/OTCMBlandingpage.php

CONTACT: OTCMarketbulls.com e-mail: [e-mail] WWW: http://www.otcmarketbulls.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].




(C)1994-2010 M2 COMMUNICATIONS
**********************************************************************
As of Thursday, 01-07-2010 23:59, the latest Comtex SmarTrend® Alert, an automated pattern recognition system, indicated a DOWNTREND on 10-05-2009 for SCLN @ $3.52.

For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright © 2004-2010 Comtex News Network, Inc. All rights reserved.